Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fruit acid B is a designation used in clinical research, specifically in trial ChiCTR2000031393, to refer to **supramolecular salicylic acid (SSA)**. Supramolecular salicylic acid is a specialized formulation of salicylic acid that utilizes supramolecular chemistry (often involving polymers like poloxamers) to create a water-soluble, controlled-release delivery system. This technology aims to maintain the keratolytic and anti-inflammatory benefits of salicylic acid while minimizing the irritation, dryness, and "frosting" often associated with traditional alcohol-based salicylic acid peels. In the context of dermatology, it is used as a chemical peeling agent for the treatment of mild to moderate acne vulgaris, where it works by exfoliating the skin, clearing pores, and reducing inflammation. Although salicylic acid is technically a beta hydroxy acid (BHA), it is frequently grouped under the general category of "fruit acid" treatments in Chinese clinical and aesthetic practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fruit acid B.